Ovid Therapeutics (OVID) Interest Coverage Ratio (2016 - 2026)
Ovid Therapeutics (OVID) posted Interest Coverage Ratio of 7.76 for Q1 2026, down 987.81% on a QoQ basis from 0.71 in Q3 2025, and down 52.65% year-over-year from 16.39 in Q1 2025.
Ovid Therapeutics (OVID) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Interest Coverage Ratio history runs 11 years deep, the most recent figure standing at 7.76 for Q1 2026.
- Quarterly Interest Coverage Ratio fell 52.65% year-over-year to 7.76 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.75 (up 10.12% YoY) and the FY2025 annual result came in at 0.47, up 32.64% from the prior year.
- Interest Coverage Ratio was 7.76 for Q1 2026 at Ovid Therapeutics, down from 0.71 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.12 in Q4 2024 and bottomed at 195.84 in Q4 2022.
- A 5-year average of 15.79 and a median of 4.8 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio tumbled 1675.96% — and 2023, when it soared 98.22%.
- Ovid Therapeutics' Interest Coverage Ratio stood at 195.84 in 2022, then jumped by 98.22% to 3.49 in 2023, then surged by 96.57% to 0.12 in 2024, then tumbled by 495.22% to 0.71 in 2025, then sank by 987.81% to 7.76 in 2026.
- Business Quant data shows OVID's Interest Coverage Ratio at 7.76 in Q1 2026, 0.71 in Q3 2025, and 2.05 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 3.88 |
| 10 | Ovid Therapeutics | 119.91 Mn | -35.61 Mn | - | -7.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.76 |
| Sep 30, 2025 | -0.71 |
| Jun 30, 2025 | -2.05 |
| Mar 31, 2025 | -5.08 |
| Dec 31, 2024 | -0.12 |
| Sep 30, 2024 | -5.71 |
| Jun 30, 2024 | -1.00 |
| Mar 31, 2024 | -4.52 |
| Dec 31, 2023 | -3.49 |
| Sep 30, 2023 | -0.54 |
| Jun 30, 2023 | -2.42 |
| Mar 31, 2023 | -6.43 |
| Dec 31, 2022 | -195.84 |
| Sep 30, 2022 | -5.53 |
| Jun 30, 2022 | -6.18 |
| Mar 31, 2022 | -5.28 |
| Dec 31, 2021 | -11.03 |
| Sep 30, 2021 | -3.88 |
| Jun 30, 2021 | -2.52 |
| Mar 31, 2021 | 27.36 |